Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline (2024)
Using AUA Guidelines
Access to AUA guidelines is provided free for individuals’ clinical use only. Anyone accessing AUA guidelines for any other purpose must obtain a license in advance. Licenses for academic, research and educational purposes can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to, and limited authorized use of AUA guidelines is a member benefit. Members are granted a limited license to access and use the AUA Guidelines for their individual, non-commercial use, for clinical, academic, educational, and research purposes, in accordance with the AUA Guidelines Terms and Conditions of Use. Members who wish to use the Guidelines for any other purpose, or in any manner not authorized by this limited license grant or by the AUA Guidelines Terms and Conditions of Use must request and obtain a license/permission in advance. Licenses for business or institutional academic, research and educational related purposes (e.g., use in course packs or for employer-sponsored research) can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to AUA guidelines is provided free for individual clinical use only, in accordance with the AUA Guidelines Terms and Conditions of Use. Anyone accessing AUA guidelines for any other purpose must obtain a license/permission in advance. Licenses for academic, research and educational purposes (e.g., in course packs or employer-sponsored research) can be requested through the AUA by contacting permissions@AUAnet.org.
Licenses for promotional or commercial use can be requested by contacting Keith Price at kprice@AUAnet.org.
Access FAQs on AUA clinical guideline usage and licensing.
By reading this guideline, you agree to AUA's Guidelines Terms and Conditions of Use.
Using AUA Guidelines
Access to AUA guidelines is provided free for health care providers for their individual clinical use only. Patients and the general public are provided a summary of the guidelines. Patients who wish to discuss the full guidelines should consult with their healthcare provider.
Guideline Resources
Unabridged PDF for this Guideline
The Journal of Urology® Article
Algorithm Associated with this Guideline
(Published 2017; Amended 2020, 2024)
Purpose
Although representing approximately 25% of patients diagnosed with bladder cancer, muscle-invasive bladder cancer (MIBC) carries a significant risk of death that has not significantly changed in decades. Increasingly, clinicians and patients recognize the importance of multidisciplinary collaborative efforts that take into account survival and quality of life (QOL) concerns. This guideline provides a risk-stratified clinical framework for the management of muscle-invasive urothelial bladder cancer and is designed to be used in conjunction with the associated treatment algorithm.
Key Takeaways
This evidence-based guideline for clinically non-metastatic muscle-invasive urothelial bladder cancer (cT2-T4N0M0) focuses on the evaluation, treatment, and surveillance of MIBC and is guided toward curative intent. The clinical guideline includes discussion of the following:
- Initial patient evaluation and counseling
- Treatment
- Bladder-preserving approaches
- Patient surveillance and follow-up
- Variant histology
Create a free account to access expanded content and resources.
AUA Clinical Practice Guidelines are developed by multidisciplinary panels of experts based on rigorous systematic review of current urologic research.
| Free Resources | |
 |
Urology A-Z Bladder Cancer |
| Login to Continue | |
| Member Benefit | |
|
Unabridged PDF for this Guideline |
|
The Journal of Urology® Article |
|
Algorithm Associated with this Guideline |